Atea Pharmaceuticals (AVIR) Cash from Operations: 2018-2024
Historic Cash from Operations for Atea Pharmaceuticals (AVIR) over the last 7 years, with Dec 2024 value amounting to -$135.5 million.
- Atea Pharmaceuticals' Cash from Operations rose 71.43% to -$21.5 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$121.0 million, marking a year-over-year decrease of 39.05%. This contributed to the annual value of -$135.5 million for FY2024, which is 58.67% down from last year.
- According to the latest figures from FY2024, Atea Pharmaceuticals' Cash from Operations is -$135.5 million, which was down 58.67% from -$85.4 million recorded in FY2023.
- Atea Pharmaceuticals' Cash from Operations' 5-year high stood at $296.7 million during FY2020, with a 5-year trough of -$135.5 million in FY2024.
- Its 3-year average for Cash from Operations is -$114.0 million, with a median of -$121.0 million in 2022.
- Its Cash from Operations has fluctuated over the past 5 years, first spiked by 2,412.99% in 2020, then crashed by 129.32% in 2021.
- Yearly analysis of 5 years shows Atea Pharmaceuticals' Cash from Operations stood at $296.7 million in 2020, then slumped by 129.32% to -$87.0 million in 2021, then plummeted by 39.05% to -$121.0 million in 2022, then grew by 29.42% to -$85.4 million in 2023, then tumbled by 58.67% to -$135.5 million in 2024.